公司概覽
業務類別 Biotechnology
業務概覽 Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
公司地址 350 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
電話號碼 +1 650 624-3000
傳真號碼 +1 650 624-3010
公司網頁 https://www.cytokinetics.com
員工數量 673
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Mr. Jeffrey J. Hessekiel Executive Vice President, Chief Legal and Administrative Officer -- 14/11/2025
Dr. Fady Ibraham Malik, M.D.,PhD Executive Vice President, Research and Development 美元 609.46K 10/04/2025
Mr. Robert I. Blum Director, President and Chief Executive Officer 美元 825.55K 26/02/2026
Mr. Sung H. Lee Executive Vice President, Chief Financial Officer and Principal Accounting Officer 美元 550.00K 26/02/2026
Mr. Andrew M. Callos Executive Vice President and Chief Commercial Officer 美元 562.91K 10/04/2025
 
董事會成員
董事會 職務 更新日期
Dr. Robert A. Harrington, M.D. Independent Director 26/02/2026
Mr. James M. Daly Independent Director 26/02/2026
Dr. John T. Henderson, M.B. Chairman of the Board 26/02/2026
Ms. Nancy J. Wysenski Independent Director 26/02/2026
Dr. Edward M. Kaye, M.D. Independent Director 26/02/2026
Dr. Wendell D. Wierenga,PhD Independent Director 26/02/2026
Mr. Robert I. Blum Director, President and Chief Executive Officer 26/02/2026
Ms. B. Lynne Parshall, Esq.,J.D. Independent Director 26/02/2026
Ms. Muna Bhanji, Ph. Independent Director 26/02/2026
Mr. Robert E. Landry Independent Director 26/02/2026
 
所屬ETF (更新日期: 07/03/2026 02:31)
代號 名稱 佔比% 持有日期
AVIEAvantis Inflation Focused Equity ETF0.0001%28/02/2026
ESLVEventide Large Cap Value ETF0.0001%27/02/2026
GTPEGoldman Sachs MSCI Wld Priv Eq RtTrkrETF0.00001%27/02/2026
AIEQAI Powered Equity ETF<0.000001%22/09/2023
AIEQAmplify AI Powered Equity ETF<0.000001%27/02/2026
AOMiShares Core 40/60 Moderate Allc ETF<0.000001%27/02/2026
BKSEBNY Mellon US Small Cap Core Equity ETF<0.000001%05/02/2026
CLSEConvergence Long/Short Equity ETF<0.000001%09/01/2026
CVLCCalvert US Large-Cp Cor Rspnb ETF<0.000001%23/06/2025
CVMCCalvert US Mid-Cp Cor Rspnb ETF<0.000001%23/06/2025
ESSCEventide Small Cap ETF<0.000001%06/02/2026
EWSCInvesco S&P SmallCap 600® Equal Wt ETF<0.000001%20/03/2023
FDIFFidelity Disruptors ETF<0.000001%02/02/2026
FSSTFidelity Sustainable U.S. Equity ETF<0.000001%31/07/2025
HKNDHumankind US Stock ETF<0.000001%24/11/2025
ISCViShares Morningstar Small-Cap Value ETF<0.000001%23/12/2025
QMOMAlpha Architect US Quantitative Momt ETF<0.000001%27/02/2026
QQQXNuveen NASDAQ 100 Dynamic Overwrite<0.000001%31/05/2025
SBIOALPS Medical Breakthroughs ETF<0.000001%22/12/2025
SMMDiShares Russell 2500 ETF<0.000001%27/02/2026
  1    2    3    4    5   6  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.